Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) shares traded up 11.8% during trading on Thursday . The stock traded as high as GBX 1.34 ($0.02) and last traded at GBX 1.33 ($0.02). 6,113,233 shares were traded during trading, a decline of 33% from the average session volume of 9,128,820 shares. The stock had previously closed at GBX 1.19 ($0.02).
Hemogenyx Pharmaceuticals Price Performance
The stock has a 50-day moving average price of GBX 1.39 and a two-hundred day moving average price of GBX 1.42. The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 92.09. The stock has a market cap of £17.82 million, a price-to-earnings ratio of -119.00 and a beta of 3.14.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Recommended Stories
- Five stocks we like better than Hemogenyx Pharmaceuticals
- Buy P&G Now, Before It Sets A New All-Time High
- A $1.75 Billion Gamble: Can Lucid Ignite Growth?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- The Rally in Lockheed Martin and RTX Can Continue: Here’s Why
- What is a Death Cross in Stocks?
- 3 Undervalued Technology Stocks With Big Rebound Potential
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.